Online citations, reference lists, and bibliographies.
← Back to Search

5-Hydroxytryptamine And The Pathophysiology Of Migraine

P. Humphrey
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Summary5-Hydroxytryptamine (5-HT; serotonin) has long been implicated in the aetiology of migraine but the evidence remains circumstantial and certainly not definitive. Numerous papers have reviewed the background which is briefly outlined here. Although the continued belief in the primary involvement of 5-HT in the genesis of a migraine attack has recently been questioned, many antimigraine drugs undeniably interact potently with 5-HT receptors. It can be argued, however, that their modest clinical benefit results from their pharmacological effects, be they mediated through 5-HT receptors or otherwise, independently of any pathophysiological involvement of endogenous 5-HT. Nevertheless, there seems convincing evidence that central release of 5-HT by various drug mechanisms causes migraine-like headache in migraineurs. It remains to be seen whether these drugs mimic the pathological event initiating the spontaneous migraine attack. Regardless of these considerations, the focus of research on 5-HT and migraine has proved to be enormously profitable over several decades, culminating recently in the identification of a novel, potentially important, antimigraine drug for the treatment of the acute attack. This drug, sumatriptan, is a selective cranial vasoconstrictor which mediates this effect by specifically activating a particular 5-HT1 receptor subtype. Undoubtedly a precise understanding of its clinical mechanism of action, which is currently being studied by a number of groups, will lead to a better understanding of the pathogenesis of migraine. Perhaps this in turn will help in finally determining whether migraine is a vascular disease and whether or not a disturbance of 5-HT is just epiphenomenal or is truly the primary initiating pathological event.
This paper references
A putative 5-HT central feedback in migraine and cluster headache attacks.
S. Salmon (1982)
10.1111/j.1526-4610.1979.hed1901014.x
Platelet Serotonin (5‐HT) and 5‐HT Releasing Factor in Plasma of Migrainous Patients
D. Mück-Šeler (1979)
10.1111/j.1468-2982.1989.tb00069.x
The Pharmacology of the Novel 5-HT1-Like Receptor Agonist, GR43175
P. Humphrey (1989)
10.1016/S0021-8707(36)90320-9
The mechanism of migraine
Alfred M. Goltman (1936)
Sumatriptan (GR43175) interacts selectively with 5-HTIB and 5-HTID binding sites
S JPeroutka (1989)
10.1007/978-94-009-0479-8_1
The distribution and biochemistry of 5-hydroxytryptamine in the cardiovascular system
T. Verbeuren (1990)
10.1111/J.1468-2982.1989.TB00070.X
GR43175 does not share the complex pharmacology of the ergots
W. Feniuk (1989)
A comparison between fluoxetine and doxepin in depressed patients
R. Remick (1989)
Sensory connections to cephalic blood vessels and their possible importance to vascular headaches. In: Rose FC (ed) Advances in headache research
MA Moskowitz (1987)
Pharmacological properties of the receptor(s) involved in the 5-hydroxytryptamine-induced contraction of the feline middle cerebral artery.
E. Hamel (1989)
10.1016/0014-2999(85)90658-2
Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin.
D. Hoyer (1985)
10.1111/j.1476-5381.1990.tb14679.x
The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater
M. G. Buzzi (1990)
10.1093/ACPROF:OSO/9780192618108.003.0012
5-HT in migraine: evidence from 5-HT1-like receptor agonists for a vascular aetiology
P. Humphrey (1990)
10.1007/BF00635900
The psychopharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects
H. Curran (2004)
10.1016/S0140-6736(85)92949-6
MIGRAINE AND INTRACRANIAL SWELLING: AN EXPERIMENT OF NATURE
J. Blau (1985)
Serotonin, migraine and platelets
JR Fozard (1982)
10.1007/BF01642900
Cerebral blood flow changes in migraine: methods, observations and hypotheses
L. Friberg (2004)
10.1001/ARCHNEURPSYC.1955.02330140015003
Arterenol (norepinephrine) and vascular headache of the migraine type; studies on headache.
A. Ostfeld (1955)
[Pathogenesis of migraine].
H. KISTELSKA-NIELUBOWICZOWA (1953)
10.1007/978-94-009-0479-8_37
A rational approach to identifying a fundamentally new drug for the treatment of migraine
P. Humphrey (1990)
10.1093/ACPROF:OSO/9780192618108.003.0011
5-HT in migraine: evidence from 5-HT receptor antagonists for a neuronal aetiology
J. Fozard (1990)
10.1159/000229055
Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine.
F. Sicuteri (1959)
Die Beeinflussung migr~ineartiger Zust~inde dutch ein sympathikushemmendes Mittel (Gynergen)
E Trautmann (1928)
10.1097/00005053-193811000-00019
THE MECHANISM OF MIGRAINE
Alfred M. Goltman (1938)
10.1097/00006842-195705000-00005
Studies in headache; summary of evidence concerning a noxious agent active locally during migraine headache.
A. Ostfeld (1957)
10.1046/j.1468-2982.1981.0103143.x
The Site of Pain Origin During Migraine Attacks
J. Blau (1981)
10.1016/S0140-6736(79)92692-8
NEUROTRANSMITTERS AND THE FIFTH CRANIAL NERVE: IS THERE A RELATION TO THE HEADACHE PHASE OF MIGRAINE?
MichaelA. Moskowitz (1979)
Basic pharmacological properties. In: Berde B, Schild HO (ed) Ergot alkaloids and related compounds. Handbook of experimental pharmacology
E Mtiller-Schweinitzer (1978)
10.1159/000229194
Biochemical Investigations in Headache: Increase in the Hydroxyindoleacetic Acid Excretion During Migraine Attacks
F. Sicuteri (1961)
10.1001/ARCHNEURPSYC.1938.02270040093005
MECHANISM OF MIGRAINE HEADACHE AND ACTION OF ERGOTAMINE TARTRATE
J. R. Graham (1938)
10.1212/WNL.39.9.1239
Serotonin metabolism in migraine
M. Ferrari (1989)
10.1001/archneurpsyc.1950.02310190058003
Studies in Headache: Summary of Evidence Concerning a Noxious Agent Active Locally During Migraine Headache
A. Ostfeld (1957)
Fenfluramine headache: a biochemical and monoamine receptorial human study. In: Sicuteri F (ed) Headache: new vistas
E Del Bene (1977)
10.1212/WNL.6.2.96
Craniovascular Studies in Headache
P. Brazil (1956)
10.1016/0306-3623(88)90051-1
Effects of ergotamine on cardiovascular catecholamine receptors in the pithed rat.
A. Badía (1988)
10.1038/316126A0
Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs
B. Richardson (1985)
10.1111/j.1476-5381.1987.tb16844.x
Pharmacological characterization of 5‐hydroxytryptamine‐induced depolarization of the rat isolated vagus nerve
S. Ireland (1987)
10.1016/0304-3959(83)90036-2
The site of pain origin during migraine attacks : J.N. Blau and S.L. Dexter, Cephalalgia, 1 (1981) 143–147
J. Blau (1981)
10.1007/BF01642906
5-HT2 receptor antagonists and migraine therapy
E. J. Mylecharane (2004)
10.1007/springerreference_105845
[Serotonin (5-hydroxytryptamine)].
M. Papara (1962)
10.1046/j.1468-2982.1985.0502079.x
Effects on Migraine Headache of MDL 72,222, an Antagonist at Neuronal 5-HT Receptors. Double-Blind, Placebo-Controlled Study
C. Loisy (1985)
10.7326/0003-4819-32-2-350_1
Headache and other head pain
H. Wolff (1972)
10.1111/j.1526-4610.1982.hed2206242.x
Spreading Cerebral Oligemia in Classical‐ and Normal Cerebral Blood Flow in Common Migraine
J. Olesen (1982)
10.1111/j.1600-0447.1987.tb02923.x
Citalopram versus maprotiline: A controlled, clinical multicentre trial in depressed patients
J. M. Bouchard (1987)
10.1007/BF01642907
5-HT3 receptor antagonists and migraine therapy
M. Ferrari (2004)
10.1007/978-1-349-10114-6_33
PathoPhysiology of 5-Hydroxytryptamine: An Overview
J. Angus (1989)
10.1111/j.1526-4610.1974.hed1403149.x
THE EFFECTS OF RESERPINE INJECTION ON METHYSERGIDE TREATED CONTROL AND MIGRAINOUS SUBJECTS
J. Carroll (1974)
10.1038/clpt.1988.83
Induction of migrainelike headaches by the serotonin agonist m‐chlorophenylpiperazine
T. Brewerton (1988)
10.1111/j.1749-6632.1990.tb16912.x
Serotonin and Migraine
P. A. Humphrey (1990)
Neurotransmitters and the fifth cranial nerve: is there a relation to headache phase of migraine? Lancet II
MA Moskowitz (1979)
Studies on headache : arterenol ( norepinephrine ) and vascular headache of the migraine type
IH Page (1955)
10.1093/BRAIN/88.5.997
Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects.
D. A. Curran (1965)
10.1111/J.1468-2982.1989.TB00075.X
Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine
V. Perrin (1989)
10.1111/j.1526-4610.1990.hed30s1012.x
Anti‐Migraine Drugs in Development: Advances in Serotonin Receptor Pharmacology
P. Humphrey (1990)
Prophylactic and therapeutic properties of 1methyl-lysergic acid butanolamide in migraine, in t Arch Allergy
F Sicuteri (1959)
10.1007/BF01642908
Rationale for the use of 5-HT1-like agonists in the treatment of migraine
W. Feniuk (2004)
10.1002/ANA.410130108
Extracranial vascular changes and the source of pain in migraine headache
P. Drummond (1983)
10.1111/j.1526-4610.1990.hed30s1005.x
The Pharmacology of Current Anti‐Migraine Drugs
S. Peroutka (1990)
10.1007/978-3-0348-7128-0_5
Pharmacology of migraine.
N. Raskin (1981)
Urinary excretion of biogenic amines camines in migraine and tension headache
Ferrari (1989)
Sumatriptan succinate
PPA Humphrey (1989)
10.1111/j.1526-4610.1975.hed1502136.x
CONCENTRATION OF SEROTONIN IN BLOOD PLATELETS: EFFECT OF RESERPINE IN MIGRAINEURS
I. Genefke (1975)
10.1016/0014-2999(89)90406-8
Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites.
S. Peroutka (1989)
10.1016/0303-8467(87)90189-2
Methionine-enkephalin and serotonin in migraine and tension headache
M. D. Ferrari (1987)
Fenfluramine headache : a biochemical and monoamine receptorial human study
E DelBene (1977)
10.1016/0304-3959(76)90009-9
Release of platelet 5-hydroxytryptamine by plasma taken from patients during and between migraine attacks
A. Dvilansky (1976)
10.1007/978-3-642-66775-6_3
Basic Pharmacological Properties
E. Müller‐Schweinitzer (1978)
10.1007/BF01642906
5-HT2 receptor antagonists and migraine therapy.
Mylecharane Ej (1991)
10.1016/0024-3205(87)90458-9
M-chlorophenylpiperazine increases blood pressure and heart rate in pithed and conscious rats.
G. Bagdy (1987)
10.1177/03331024850050S3158
Ketanserin a Selective Serotonin Antagonist, in Relation to Platelet Aggregation and Migraine Attack Rate
K. Winther (1985)
10.1111/j.2042-7158.1982.tb04788.x
Ketanserin—a novel antihypertensive drug?
P. Humphrey (1982)
10.1016/0165-6147(89)90061-8
5-HT1C receptor activation: a key step in the initiation of migraine?
J. Fozard (1989)
10.1001/archderm.1965.01600130122028
Substances producing pain and itch
C. Keele (1964)
10.1136/jnnp.36.4.684
Amitriptyline in migraine prophylaxis
J. Gomersall (1973)
10.1016/0165-6147(88)90174-5
Molecular pharmacology and biology of 5-HT1C receptors.
D. Hoyer (1988)
10.1016/0006-2952(84)90424-6
Serotonin-releasing effects of substituted piperazines in vitro.
D. Pettibone (1984)
10.1136/jnnp.29.1.85
Excretion of 5-hydroxyindolyl acetic acid (5HIAA) in migraine.
G. Curzon (1966)
10.1016/0166-2236(86)90008-1
Migraine and regional cerebral blood flow
P. Gloor (1986)
10.1016/0304-3940(85)90045-X
Calcitonin gene-related peptide is present in mammalian cerebrovascular nerve fibres and dilates pial and peripheral arteries
J. Hanko (1985)
10.1097/00007611-195605000-00031
Pain : its mechanisms and neurosurgical control
J. C. White (1955)
10.1111/j.1526-4610.1968.hed0803118.x
DOUBLE‐BLIND CROSSOVER COMPARISON OF BC‐105, METHYSERGIDE AND PLACEBO IN THE PROHYLAXIS OF MIGRAINE HEADACHE
R. Ryan (1968)
Efficacy and tolerability of ICS 205-930, a 5-HT3 receptor antagonist, in migraine
X Lataste (1989)
Migraine headache and blood serotonin levels after administration of zimelidine, a selective inhibitor of serotonin uptake
E Syvfitahti (1979)
New product in the treatment of migraine; preliminary report
BT Horton (1945)
10.1001/ARCHNEURPSYC.1941.02280140009001
EXPERIMENTAL STUDIES ON HEADACHE: A. CONTRAST OF HISTAMINE HEADACHE WITH THE HEADACHE OF MIGRAINE AND THAT ASSOCIATED WITH HYPERTENSION B. CONTRAST OF VASCULAR MECHANISMS IN PREHEADACHE AND IN HEADACHE PHENOMENA OF MIGRAINE
G. A. Schumacher (1941)
10.1159/000387453
The Possible Relationship of Serotonin to the Migraine Syndrome
M. Anthony (1969)
10.1001/ARCHNEUR.1967.00470230096013
Plasma serotonin in migraine and stress.
M. Anthony (1967)
10.1111/J.1526-4610.1967.HED0703134.X
The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome.
J. Lance (1967)
10.1136/jnnp.33.6.891
THE MECHANISM AND MANAGEMENT OF HEADACHE
C. Whitty (1970)
Le traitement des migraines par le tartrate d ' ergotamine
A Tzanck (1928)
Urinary excretion of biogenic amines camines in migraine and tension headache. In: Rose FC (ed) New advances in headache research
MD Ferrari (1989)
10.1161/01.STR.21.4.555
Focal headache during balloon inflation in the internal carotid and middle cerebral arteries.
F. Nichols (1990)
10.1161/01.STR.9.6.594
Ergotamine and Cerebral Blood Flow
V. Hachinski (1978)
10.1136/BMJ.285.6347.1009
Severe headache and disturbed liver function during treatment with zimelidine.
J. Sommerville (1982)
10.1177/0333102489009S10184
Efficacy and Tolerability of ICS 205–930, A 5-HT3 Receptor Antagonist, in Migraine Prophylaxis
X. Lataste (1989)
10.1136/jnnp.27.5.463
Clinical trial of methysergide and other preparations in the management of migraine
D. A. Curran (1964)
10.1111/j.2042-7158.1975.tb09448.x
The animal pharmacology of drugs used in the treatment of migraine
J. Fozard (1975)
Effects on migraine headache of MDL72222 an antagonist at neuronal 5-HT receptors
C Loisy (1985)
Ergo - tamine and cerebral blood flow
E Hamel (1978)
Sensory connections to cephalic blood vessels and their possible importance to vascular headaches
FC Rose (1987)
10.1007/BF01642898
What is migraine? Controversy and stalemate in migraine pathophysiology
J. Edmeads (2004)
10.1002/ANA.410160202
The neurobiology of vascular head pain
M. Moskowitz (1984)
10.1016/0024-3205(83)90303-X
Antagonism of vascular serotonin receptors by m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine.
M. Cohen (1983)
10.1001/ARCHSURG.1940.01210040002001
EXPERIMENTAL STUDIES ON HEADACHE: PAIN-SENSITIVE STRUCTURES OF THE HEAD AND THEIR SIGNIFICANCE IN HEADACHE
B. S. Ray (1940)



This paper is referenced by
10.1016/S0072-9752(10)97004-8
Chapter 4 – Pharmacology
H. Bolay (2010)
10.1097/01.fjc.0000159639.59770.36
Triptans Induce Vasoconstriction of Human Arteries and Veins from the Thoracic Wall
A. Wackenfors (2005)
Systemic administration of nitric oxide donor nitroglycerin as an experimental model for migraine headache in rats
Párdutz Árpád (2004)
10.1016/S0163-7258(02)00173-0
New insights into the molecular actions of serotonergic antimigraine drugs.
P. Durham (2002)
10.1007/BF01642907
5-HT3 receptor antagonists and migraine therapy
M. Ferrari (2004)
10.1111/j.1526-4610.2008.01230.x
The Mode of Action of Migraine Triggers: A Hypothesis
G. Lambert (2009)
10.1177/0333102416640501
Serotonergic mechanisms in the migraine brain – a systematic review
M. Deen (2017)
10.2217/FNL.09.14
Migraine: an endemic disease inside the blood–brain barrier
C. Dahlöf (2009)
10.1007/978-3-319-54726-8_16
Pediatric and Adolescent Headache and Obesity
T. Eidlitz-Markus (2017)
Historical Perspectives on Rural Medicine
C. Overy (2017)
10.1111/j.1468-2982.2007.01476.x
Serotonin and Migraine: Biology and Clinical Implications
E. Hamel (2007)
10.1155/2019/9685750
Application of Factorial and Doehlert Designs for the Optimization of the Simultaneous Separation and Determination of Antimigraine Drugs in Pharmaceutical Formulations by RP-HPLC-UV
Sami Jebali (2019)
10.1177/0091270003254638
Pharmacokinetics of Sumatriptan Nasal Spray in Adolescents
M. Christensen (2003)
10.1016/j.drugalcdep.2011.10.029
Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.
M. Johnson (2012)
10.2217/nnm.10.28
Formulation and evaluation of novel micellar nanocarrier for nasal delivery of sumatriptan.
R. Jain (2010)
10.1016/j.pain.2012.01.005
mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene–related peptide in the rat trigeminovascular system
D. Amrutkar (2012)
10.18632/oncotarget.9367
Molecular factors in migraine
M. Kowalska (2016)
10.1517/14656566.2013.806487
Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs
Martha B. Ramírez Rosas (2013)
10.1007/s11916-018-0696-2
Obesity and Migraine in Childhood
Tal Eidlitz Markus (2018)
NEW MOLLECULES IN MIGRAINE TREATMENT
Adina Roceanu (2015)
silocybin dose-dependently causes delayed , transient headaches in healthy olunteers atthew
W. Johnsona (2011)
10.1111/j.1474-8673.2009.00430.x
Effect of central serotonin depletion on 5-HT receptor-mediated vasomotor responses in the middle meningeal artery of anaesthetized rats.
E. Martínez-García (2009)
10.1111/j.1526-4610.2010.01632.x
Selective Inhibition of 5‐HT7 Receptor Reduces CGRP Release in an Experimental Model for Migraine
X. Wang (2010)
Aurasiz migrende trombosit serotonin düzeylerinin değerlendirilmesi Evaluation of platelet serotonin levels in migraine without aura
Sunay Ayalp (2012)
10.1016/S0014-2999(02)01436-X
Is the 5-HT(7) receptor involved in the pathogenesis and prophylactic treatment of migraine?
J. A. Terrón (2002)
10.1007/s10554-014-0456-2
Evaluation of right ventricle functions and serotonin levels during headache attacks in migraine patients with aura
E. Kalaycıoğlu (2014)
10.1177/0333102414554661
Study of neurovascular coupling during cold pressor test in patients with migraine
A. Fabjan (2015)
10.1155/2016/1846296
Electroacupuncture Pretreatment at GB20 Exerts Antinociceptive Effects via Peripheral and Central Serotonin Mechanism in Conscious Migraine Rats
Lu Liu (2016)
Serotonin Transporter Gene Polymorphisms and Harm Avoidance Personality in Chronic Tension Type Headache and Migraine
J. W. Park (2005)
10.1007/978-1-4419-9068-6_3
Disturbances of Pain Perception in Primary Headache: Migraine, Tension-type, and Cluster Headaches
A. Pielsticker (2004)
10.1016/B978-0-7020-4344-4.00004-3
Chapter 4 – Pharmacology
Nicholas T.L. Southorn (2013)
10.1097/01.YIC.0000080803.87368.01
Migraine headache prophylaxis and treatment with low-dose mirtazapine.
E. Lévy (2003)
See more
Semantic Scholar Logo Some data provided by SemanticScholar